Pharmacokinetics and Safety of a New Parenteral Carbapenem Antibiotic, Biapenem (L-627), in Elderly Subjects
Open Access
- 1 June 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (6) , 1433-1436
- https://doi.org/10.1128/aac.42.6.1433
Abstract
The pharmacokinetics and tolerability of a new parenteral carbapenem antibiotic, biapenem (L-627), were studied in healthy elderly volunteers aged 65 to 74 years (71.6 ± 2.7 years [mean ± standard deviation], n = 5; group B) and ≥75 years (77.8 ± 1.9 years, n = 5; group C), following single intravenous doses (300 and 600 mg), and compared with those of healthy young male volunteers aged 20 to 29 years (23.0 ± 3.5 years, n = 5; group A). The agent was well tolerated in all three age groups. Serial blood and urine samples were analyzed for biapenem to obtain key pharmacokinetic parameters by both two-compartment model-dependent and -independent methods. The maximum plasma concentration and area under plasma concentration-versus-time curve (AUC) increased in proportion to the dose in all three groups. Statistically significant age-related effects for AUC, total body clearance, and renal clearance (CL R ) were found, while elimination half-life ( t 1/2β ) and percent cumulative recovery from urine of unchanged drug (% UR) remained unaltered ( t 1/2β , 1.51 ± 0.42 [300 mg] and 2.19 ± 0.64 [600 mg] h [group A], 1.82 ± 1.14 and 1.45 ± 0.36 h [group B], and 1.75 ± 0.23 and 1.59 ± 0.18 h [group C]; %UR, 52.6% ± 3.0% [300 mg] and 53.1% ± 5.1% [600 mg] [group A], 46.7% ± 7.4% and 53.0% ± 4.8% [group B], and 50.1% ± 5.2% and 47.1% ± 7.6% [group C]). A significant linear correlation was observed between the CL R of biapenem and creatinine clearance at the dose of 300 mg but not at 600 mg. The steady-state volume of distribution tended to be decreased with age, although not significantly. Therefore, the age-related changes in parameters of biapenem described above were attributable to the combination of decreased lean body mass and lowered renal function of the elderly subjects. However, the magnitude of those changes does not necessitate dosage adjustment in elderly patients with normal renal function for their age.Keywords
This publication has 14 references indexed in Scilit:
- Adverse Effects of Monobactams and CarbapenemsDrug Safety, 1995
- Review: The Frequency and Severity of Adverse Drug Reactions in Elderly PeopleAge and Ageing, 1994
- Pharmacokinetic Studies in Elderly PeopleClinical Pharmacokinetics, 1994
- The need for pharmacokinetics protocols in special casesPharmacological Research, 1993
- Effects of age and gender on pharmacokinetics of cefepimeAntimicrobial Agents and Chemotherapy, 1992
- Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibioticAntimicrobial Agents and Chemotherapy, 1992
- In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase IAntimicrobial Agents and Chemotherapy, 1990
- Clinical Pharmacokinetics of Antibacterial Drugs in the ElderlyClinical Pharmacokinetics, 1989
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Adult lean body mass declines with age: Some longitudinal observationsMetabolism, 1970